We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+8.21%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$214M
AUM Growth
+$9.71M
Cap. Flow
-$616K
Cap. Flow %
-0.29%
Top 10 Hldgs %
6.68%
Holding
490
New
42
Increased
186
Reduced
165
Closed
36

Top Buys

Rank Stock Value
1
OCCI
OFS Credit Co
OCCI
+$2.05M
2
HYG icon
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
+$1.92M
3
ECC
Eagle Point Credit Company
ECC
+$1.26M
4
APP icon
Applovin
APP
+$1.04M
5
CEG icon
Constellation Energy
CEG
+$1.01M

Top Sells

Rank Stock Value
1
OXLC
Oxford Lane Capital
OXLC
+$1.49M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.06M
3
GEN icon
Gen Digital
GEN
+$1.01M
4
ADBE icon
Adobe
ADBE
+$989K
5
STE icon
Steris
STE
+$907K

Sector Composition

Rank Sector Weight
1 Financials 28.16%
2 Healthcare 18.37%
3 Technology 14.33%
4 Industrials 8.16%
5 Consumer Discretionary 6.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
351
Protagonist Therapeutics
PTGX
$8.55B
$121K 0.06%
2,680
+45
+2% +$1.82K
EC icon
352
Ecopetrol
EC
$33.7B
$120K 0.06%
13,484
-2,962
-18% -$30K
GPRK icon
353
GeoPark
GPRK
$609M
$120K 0.06%
15,205
-3,874
-20% -$35.5K
NUVL
354
DELISTED
Nuvalent
NUVL
$119K 0.06%
1,165
+19
+2% +$1.58K
WVE icon
355
Wave Life Sciences
WVE
$1.12B
$117K 0.05%
14,222
+252
+2% +$1.51K
IRON icon
356
Disc Medicine
IRON
$2.81B
$116K 0.05%
2,353
+41
+2% +$1.93K
ERAS icon
357
Erasca
ERAS
$6.15B
$115K 0.05%
42,275
+749
+2% +$2.11K
ABUS icon
358
Arbutus Biopharma
ABUS
$847M
$112K 0.05%
29,162
+515
+2% +$1.98K
VKTX icon
359
Viking Therapeutics
VKTX
$3.88B
$112K 0.05%
1,771
+33
+2% +$1.94K
COGT icon
360
Cogent Biosciences
COGT
$6.76B
$111K 0.05%
10,266
+185
+2% +$1.8K
TYRA icon
361
Tyra Biosciences
TYRA
$1.85B
$109K 0.05%
4,642
+82
+2% +$1.72K
MLTX icon
362
MoonLake Immunotherapeutics
MLTX
$1.56B
$109K 0.05%
2,162
+42
+2% +$1.97K
VERA icon
363
Vera Therapeutics
VERA
$2.33B
$109K 0.05%
2,465
+45
+2% +$1.71K
KROS icon
364
Keros Therapeutics
KROS
$197M
$108K 0.05%
1,859
+30
+2% +$1.48K
AKRO
365
DELISTED
Akero Therapeutics
AKRO
$107K 0.05%
3,741
+64
+2% +$1.67K
ELVN icon
366
Enliven Therapeutics
ELVN
$3.78B
$107K 0.05%
4,188
+77
+2% +$1.78K
REPL icon
367
Replimune Group
REPL
$454M
$107K 0.05%
9,739
+170
+2% +$1.73K
CATX icon
368
Perspective Therapeutics
CATX
$327M
$106K 0.05%
7,945
+142
+2% +$1.89K
RNAM
369
DELISTED
Avidity Biosciences
RNAM
$106K 0.05%
2,305
+40
+2% +$1.74K
RVMD icon
370
Revolution Medicines
RVMD
$38.5B
$105K 0.05%
2,321
+43
+2% +$1.87K
SLRN
371
DELISTED
ACELYRIN
SLRN
$104K 0.05%
21,138
+375
+2% +$1.94K
SLNO
372
DELISTED
Soleno Therapeutics
SLNO
$104K 0.05%
2,050
+39
+2% +$1.87K
ALLO icon
373
Allogene Therapeutics
ALLO
$625M
$102K 0.05%
36,285
+645
+2% +$1.72K
CRNX icon
374
Crinetics Pharmaceuticals
CRNX
$8.88B
$100K 0.05%
1,962
+31
+2% +$1.6K
CGON icon
375
CG Oncology
CGON
$6.1B
$99.9K 0.05%
2,648
+47
+2% +$1.65K
13 14
15
16 17

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q3 2024 Portfolio in Review

As of Q3 2024, Virtus ETF Advisers held 490 positions worth $214M, up 4.8% from $204M the previous quarter. Its ten largest holdings account for 6.7% of the portfolio.

Virtus ETF Advisers's Q3 2024 filing shows 42 new, 186 increased, 165 reduced and 36 closed positions. Its largest new stake was OFS Credit Co: 278,579 shares worth $2.06M. The largest sale was Oxford Lane Capital, an estimated $1.49M.

By sector, the portfolio is most concentrated in Financials at 28% of assets, up from 27% a quarter earlier, followed by Healthcare and Technology.

  • Virtus ETF Advisers's largest Q3 2024 buy was OFS Credit Co: 278,579 shares worth $2.06M.
  • Virtus ETF Advisers added most to Public Storage in Q3 2024, an estimated $927K increase.
  • Virtus ETF Advisers's biggest Q3 2024 reduction was Regeneron Pharmaceuticals, cutting an estimated $1.06M.
  • Virtus ETF Advisers fully exited Oxford Lane Capital in Q3 2024, selling an estimated $1.49M.
  • Virtus ETF Advisers's ten largest holdings make up 6.7% of its $214M portfolio in Q3 2024.
  • Virtus ETF Advisers opened 42 new positions and closed 36 in Q3 2024.
  • Virtus ETF Advisers's portfolio value rose 4.8% quarter-over-quarter to $214M.

Based on Virtus ETF Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.